Targeting this glycosaminoglycan complex biomolecules might be a novel therapeutic strategy to treat disorders such as cancers, neurodegenerative diseases, and infections associated with receptor for advanced glycation end-products (RAGE) containing disaccharide units (CS-E) [2]. The gene discussed is AGER; the disease is cancer.